All stock lists
Alto Neuroscience, Inc. (New York Stock Exchange:ANRO)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
22.12+0.15 (+0.68%)
Insider Score
––Not scored
ANRO Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ANRO Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 184.00 K | 0.00 | 0.00 | 100.00 K | 0.00 |
| Gross Profit | 0.00 | -184.00 K | 0.00 | 0.00 | -100.00 K | 0.00 |
| SG&A Expense | 7.02 M | 6.84 M | 5.06 M | 4.43 M | 5.56 M | 5.70 M |
| R&D Expense | 22.11 M | 20.29 M | 12.00 M | 10.53 M | 13.12 M | 9.97 M |
| Operating Expenses | 29.13 M | 26.95 M | -115.67 M | 14.95 M | 18.58 M | 15.68 M |
| Operating Income | -29.13 M | -27.14 M | 115.67 M | -14.95 M | -18.68 M | -15.68 M |
| Pretax Income | -27.64 M | -26.24 M | -16.18 M | -14.18 M | -17.71 M | -15.17 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -27.64 M | -26.24 M | -16.18 M | -14.18 M | -17.71 M | -15.17 M |
| EPS (Basic) | -0.65 | -0.80 | -0.51 | -0.52 | -0.65 | -0.56 |
| EPS (Diluted) | -0.65 | -0.80 | -0.51 | -0.52 | -0.65 | -0.56 |
| Shares Outstanding | 42.81 M | 32.89 M | 31.92 M | 27.10 M | 27.07 M | 27.05 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.